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Objective: Despite an earlier detection of prostate cancer (Pca) is promising, pathologically advanced
disease still exists in 40e52% of cases. We present a retrospective study of adjuvant radiotherapy (ART) in
adverse pathological tumor characteristics of PCa, and analyze the optimal time for ART.
Materials and methods: From 2004 to 2012, we identiﬁed 53 men with adverse pathological character-
istics of PCa receiving early [< 3 months after radical prostatectomy (RP), n¼ 42] or delayed (3e12
months after RP, n¼ 11) ART after RP. The adverse pathological characteristics of PCa were deﬁned as
positive surgical margins, extracapsular extension, seminal-vesicle invasion, or detectable prostate-
speciﬁc antigen after RP. The primary-outcome collection includes 5-year biochemical-free survival
(BCFS), PCa-speciﬁc mortality, bone-related events, salvage-hormonal-therapy utilization, and inter-
vention for urethral stricture.
Results: There was no PCa-speciﬁc mortality in the 5-year follow-up. When compared with the delayed
ART in men with adverse pathological characteristics of PCa, early ART was associated with the trend to
improve the 5-year BCFS (89% vs. 73%; p¼ 0.1) and less salvage hormonal therapy (45% vs. 54%; p¼ 0.29).
The delayed ART is associated with the trend of fewer urethral strictures (9% vs. 14 %; p¼ 0.32). But, there
was no signiﬁcant difference between both groups.
Conclusion: Compared with the delayed ART, early ART for adverse pathological tumor characteristics of
PCa seems to have the trend in improvement in the 5-year BCFS and metastasis-free survival. Because of
our limited case number, a prospective study with more cases to conﬁrm the effect of ART is needed.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In Taiwan, prostate cancer (PCa) is the ﬁfth and seventh leading
cancer incidence and cause of cancer death in men, respectively. In
addition, metastatic PCa is signiﬁcantly higher in Taiwanese pop-
ulation than in the general American population (32.7% vs. 5%). The
widespread use of serum prostate-speciﬁc-antigen (PSA) screening
has increased the detection of early PCa.1 PCa is gradually early-
stage migration due to broadly PSA screening, but locally advancedtment of Surgery, Tri-Service
ter, Number 325, Section 2,
ROC. Tel.: þ886 2 87927169;
14@gmail.com (S.-T. Wu).
ociation. Published by Elsevier Tadisease still estimated more than one-third PCa population in
Taiwan.2
Radical prostatectomy (RP) remains the most common and
standard treatment for clinically localized PCa with proven long-
term cancer control compared with other treatment options.3
However, the adverse pathological characteristics of PCa, deﬁned
as positive surgical margins (PSMs), extracapsular extension (ECE),
seminal-vesicle invasion (SVI), or detectable PSA after RP pre-
sented, would increase the risk of biochemical recurrence after RP.
Previous prospective randomized trials showed that, in node-
negative patients with ECE, SVI, or PSM, adjuvant radiotherapy
(ART) might have a favorable impact on biochemical and local
recurrence rate.4 However, the optimal timing for ART for maximal
beneﬁt remains unclear.
To further clarify the timing of ART in patients with advanced
PCa in Taiwan, we aimed to identify the pathological tumoriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Study participant characteristics.
Early
ART
Delayed
ART
p
Number, n 42 11
Age (y) 65.95 62.27 0.14
RPeART interval (d) 42 149
p-Gleason score 7.7 7.5 0.33
p-T stage p3a.p3b 25 8
>p3c 17 3
Initial PSA (ng/dL) 18 12.33 0.11
Risk group (%) Low and intermediate 14 10
High 78 80
Very high 8 10
PSA nadir (ng/dL) 1.76 1.34 0.3
Pathological data (%)
Positive surgical margins 95 93
Extracapsular extension 68 27
Seminal-vesicle invasion 12 15
Sexual function (%) 83 85
ART ¼ adjuvant radiotherapy; p- ¼ pathological; PSA ¼ prostate-speciﬁc antigen;
RP ¼ radical prostatectomy.
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year biochemical-free-survival (BCFS) and cancer-speciﬁc-
mortality rates, and to evaluate the complication events in the
different time of ART intervention.
2. Materials and methods
Between June 2004 and June 2012, data were retrospectively
collected for the purposes of clinical care from 352 patients who
underwent robot-assisted RP at our hospital by a single surgeon.
Eligible patients with clinical localized PCa must have under-
gone RP and pelvic-lymph-node dissection, and conform to be
pathological T3 disease or have at least one of the adverse patho-
logical characteristics, such as PSM or detectable PSA after RP. All
patients were evaluated and conﬁrmed without distal metastases
before RP and no regional-lymph-node metastases after pelvic-
lymph-node dissection. The additional eligibility requirements
were adequate bone-marrow function, an Eastern Cooperative
Oncology Group performance status of 0 through 2, no total urinary
incontinence, no pelvic infection or urinary extravasation, and no
history of intraoperative rectal injury. No prior radiotherapy or
chemotherapy for PCa was allowed.
According to the timing of ART, the patients were divided into
two groups: Group 1 (early ART, < 3 months after RP) and Group 2
(delayed ART, 3e12 months after RP). The deﬁnitions used for
complications were adapted from the Clavien grading system.5 The
primary-outcome collection includes 5-year BCFS, PCa-speciﬁc
mortality (PCSM), bone-related events (BREs), salvage-hormonal-
therapy utilization, and intervention for urethral stricture.
2.1. Robotic-assisted RP
All surgeries were performed by a single surgeon, using a da
Vinci standard four-arm surgical system (Intuitive Surgical, Sun-
nyvale, CA, USA).
2.2. Adjuvant radiotherapy
For three-dimensional conformal planning, the clinical target
volume included prostate bed, the bottom of the bladder, and the
anterior rectal wall with a margin of 0.5 cm. The inverse treatment
planning was performed using the TomoTherapy Treatment Plan-
ning software (Philips pinnacle, Elekta Synergy produced by UK). A
total dose of 68.0 Gy was prescribed to 95% of the clinical target
volume in 34 fractions. Treatment with helical tomotherapy was
performed with full bladder and empty rectum under daily image
guidance.
2.3. Primary outcomes
The assessment of PCa with ART included 5-year BCFS, PCSM,
BRE, and the use of salvage hormonal therapy (deﬁned as androgen
deprivation therapy administered after RP, without any injections 6
months prior, so as to distinguish from hormonal therapy used in
conjunctionwith ART). Additionally, postoperative intervention for
urethral stricture was identiﬁed and compared using previously
deﬁned methods. Urinary incontinence was not included as an
outcome, as this is most accurately assessed with validated patient
questionnaires.
2.4. Ethics statement
All clinical investigations were in accordance with the ethical
guidelines of the Declaration of Helsinki. Ethical approval wasobtained from the Institutional Review Board of the Tri-Service
General Hospital.2.5. Statistical analysis
The quantitative descriptive data were expressed as
mean ± standard deviation. The qualitative descriptive data were
expressed as percentages. A Chi-square test or Fisher's exact test
was used for categorical variables. The quantitative descriptive
variables were analyzed by independent-sample Student t test. The
patient survival between two groups was calculated with
KaplaneMeier survival analysis and compared with the log-rank
tests. Statistical analyses were performed using SPSS version 16.0
(SSPS Inc., Chicago, IL, USA). A value of p< 0.05was considered to be
signiﬁcant.3. Results
Early ART was undergone under stable wound condition. The
timing of ART was not randomized, because it depended on the
decision of the patient himself and his clinical physician. A total of
53 patients were enrolled, which were divided into two groups; 42
patients received early ART (<3 months after RP) and 11 patients
had delayed ART (3e12 months after RP), respectively. The preop-
erative characteristics of the patients are summarized in Table 1.
There was no signiﬁcant difference in age (70 vs. 62, p¼ 0.14),
pathological Gleason score (7.7 vs. 7.5, p¼ 0.33), and initial PSA
level (18.0 vs. 12.3, p¼ 0.113) between the two groups. The mean
interval of RP and radiotherapy was signiﬁcantly different in both
groups (42 days vs. 149 days). The indication of ART is varied (PSM
in 96% cases, ECE or SVI (pT3) in 84%, and detectable PSA in 58%).
The nadir serum PSA level in patients without undetectable serum
PSA after RP is not different between the two groups (1.76 vs. 1.34,
p¼ 0.3). The postoperative irradiation doses were set up at 68 Gy,
because most of the enrolled patients were in the higher-risk group
than the previous three Randomized-control trials (RCT). Besides,
postoperation PSA nadir is almost above 1 ng/dL. After ART, there
was no signiﬁcant difference in both groups, but the early group
compared with the delayed group had the trend of better 5-year
BCFS (89% vs. 73%, p¼ 0.1) and less combined-hormone-therapy
rate (45% vs. 54%, p¼ 0.29). In our study data, no grade 3/4
adverse effects of urethral stricture were found, and the delayed
group comparedwith the early group had the trend of less urethral-
Table 2
Timing of adjuvant radiotherapy for pathological advanced prostate cancer.
Early
ART
Delayed
ART
p
Number, n 42 11
Five-year BCR-FS (%) 89 73 0.1
PSA doubling time (mo) 56 50
PSA time to nadir (mo) 6 15
Combined hormone
therapy (%)
45 54 0.29
Five-year CSS (%) 100 100
Urethral stricture 14% (6) 9% (1) 0.32
Urethral sounding 100% (6) 100% (1)
Internal urethrotomy
or urine diversion
16% (1) 0%
ART, adjuvant radiotherapy; BCR-FS ¼ biochemical-recurrence-free survival;
CSS ¼ cancer-speciﬁc survival.
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urethral strictures could be managed with urethral sounding under
local anesthesia, except one patient who received internal ure-
throtomy in the early group (Table 2).
4. Discussion
Previously published randomized trials indicated that ART de-
creases the rate of biochemical recurrence, especially in pT3 disease
and/or PSMs.6e8 In the Southwest Oncology Group (SWOG) 8794
study, American Oncology Association (ART) resulted in signiﬁ-
cantly reduced risk of PSA relapse and disease recurrence, but the
improvements in metastasis-free survival and overall survival were
not statistically signiﬁcant. In the European Organisation for
Research and Treatment of Cancer (EORTC) 22911 study, immediate
external irradiation after radical prostatectomy also had beneﬁts in
biochemical progression-free survival and local control in patients
with PSMs or pT3 PCa. In the ARO 96-02 study, Gleason score> 6,
pT stage> pT3b, PSMs, preoperative PSA level> 10 ng/mL, and
radiotherapy are signiﬁcant prognostic factors.
In the largest case-number study (n¼ 25,000) with a long
follow-up period (15 years), published by Eggener et al,3 PSMs do
not inﬂuence PCSM. But, most patients in that trial belong to low-
and intermediate-risk prostate cancer.3 On multivariable analyses,
Abdollah et al4 found that only pathological Gleason score 8,
pT3b/T4 stage, and the presence of positive lymph nodes repre-
sented the independent predictors of cancer-speciﬁc mortality. ART
signiﬁcantly improved the survival rate only in patientswith at least
two of the following pathological features at RP: Gleason score 8,
pT3/pT4disease, and positive lymphnodes. These patients,whohad
advanced pathological features, represent the ideal candidates for
ART after RP.4 In those clinical trials, the postoperative irradiation
dose is 60 Gy, which is delivered over 6weeks in previous three RCT,
but those enrolled patients had more percentage in low-/interme-
diate-risk group and lower PSA nadir level. The operationmethod is
also quite different, but most patients received open RP. More uri-
nary incontinence or sexual dysfunctionwas found in open RP. This
may be a reason about the relative lower dose of ART.
The timing of ART is still controversial. Immediate ART < 5
months after RP for pT3 is associated with improved PCSM and
fewer BREs, and less use of salvage hormonal therapy. However,
delayed ART is associated with fewer urethral strictures.9 In our
study, we considered the strategy of the combination with
advanced robotic surgery and more aggressive monitorpostoperation PSA. Since the complications of urethral inconti-
nence and stricture in robot surgery are lower than traditional open
surgery, the 68 Gy might be suitable for our patients. The main aim
in PCa research, therefore, should be to better identify and deﬁne
lethal PCa to avoid overtreatment and to develop new and more
effective targeted therapies.
The small sample size and retrospective design were the limi-
tation of our study. Our results demonstrated no signiﬁcance in
clinical outcomes and survival-rate comparison between the two
groups. Besides, there was a very different case number in our
study. In our hospital experience, early ART was preferred than
delayed ART for pathologically advanced PCa before 2011. However,
our therapeutic strategy for timing of ART shifted to depend on
beyond T3b, undetectable PSA level, and urethral condition. Larger
samples are needed to further corroborate our results in the future.
With the improvement of intensive care and the selection of listing
criteria, we suggest that ART is safe and effective in PCa with
adverse pathological characteristics.
Compared with delayed ART, early ART for adverse pathological
tumor characteristics of PCa seems to have the trend in improving
the 5-year BCFS and metastasis-free survival. However, there is no
signiﬁcant difference for overall survival between the two groups.
Considering the pathological stage 3a/b and mild urethral incon-
tinence, delayed ART was the alternative choice for these patients.
Because of our limited case number, a prospective study with more
cases to conﬁrm the effect of ART is needed.
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